WO2011139256A3 - Stable rosuvastatin formulations - Google Patents

Stable rosuvastatin formulations Download PDF

Info

Publication number
WO2011139256A3
WO2011139256A3 PCT/TR2011/000135 TR2011000135W WO2011139256A3 WO 2011139256 A3 WO2011139256 A3 WO 2011139256A3 TR 2011000135 W TR2011000135 W TR 2011000135W WO 2011139256 A3 WO2011139256 A3 WO 2011139256A3
Authority
WO
WIPO (PCT)
Prior art keywords
formulations
rosuvastatin
stable
stabilizer
rosuvastatin formulations
Prior art date
Application number
PCT/TR2011/000135
Other languages
French (fr)
Other versions
WO2011139256A2 (en
Inventor
Bilgic Mahmut
Original Assignee
Bilgic Mahmut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TR2010/09397A external-priority patent/TR201009397A2/en
Application filed by Bilgic Mahmut filed Critical Bilgic Mahmut
Priority to EP11725996A priority Critical patent/EP2566465A2/en
Publication of WO2011139256A2 publication Critical patent/WO2011139256A2/en
Publication of WO2011139256A3 publication Critical patent/WO2011139256A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to new rosuvastatin formulations prepared so as to be used in the treatment of hyperlipidemia. The characteristic features of the formulations are that a pharmaceutically acceptable phosphate salt is used as the stabilizer and the ratio of rosuvastatin to the stabilizer in the formulation is in the range of 0.5-20 by weight.
PCT/TR2011/000135 2010-05-04 2011-05-03 Stable rosuvastatin formulations WO2011139256A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP11725996A EP2566465A2 (en) 2010-05-04 2011-05-03 Stable rosuvastatin formulations

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
TR201003542 2010-05-04
TR2010/03542 2010-05-04
TR2010/09397 2010-11-11
TR2010/09397A TR201009397A2 (en) 2010-11-11 2010-11-11 Pharmaceutical compositions containing rosuvastatin.

Publications (2)

Publication Number Publication Date
WO2011139256A2 WO2011139256A2 (en) 2011-11-10
WO2011139256A3 true WO2011139256A3 (en) 2012-05-18

Family

ID=44462116

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000135 WO2011139256A2 (en) 2010-05-04 2011-05-03 Stable rosuvastatin formulations

Country Status (2)

Country Link
EP (1) EP2566465A2 (en)
WO (1) WO2011139256A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201009397A2 (en) * 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Pharmaceutical compositions containing rosuvastatin.
DK2844233T3 (en) * 2012-05-01 2020-07-13 Althera Life Sciences Llc ORAL TABLE CONSTRUCTION CONSISTING OF A PROVIDED COMBINATION OF ROSUVASTATIN AND EZETIMIB FOR THE TREATMENT OF HYPERLIPIDIA AND CARDIOVASCULAR DISEASES
US10376470B2 (en) 2012-05-01 2019-08-13 Althera Life Sciences, Llc Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases
KR20150079373A (en) 2013-12-30 2015-07-08 한미약품 주식회사 Composite formulation for oral administration comprising ezetimibe and rosuvastatin
EP3243506A1 (en) 2016-05-09 2017-11-15 Adamed sp. z o.o. Pharmaceutical composition
BR112019009709A2 (en) * 2016-11-15 2019-08-13 Lg Chemical Ltd combination preparation.
GR1009727B (en) * 2018-11-28 2020-04-14 Elpen Αε Φαρμακευτικη Βιομηχανια Monolithic stable pharmacotechnical form of rapidly released ezetimibe and rosuvastatin

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1336405A1 (en) * 2002-02-14 2003-08-20 Ranbaxy Laboratories, Ltd. Formulations of atorvastatin stabilized with alkali metal additions
WO2008101723A2 (en) * 2007-02-23 2008-08-28 Krka Pharmaceutical composition containing a cholesterol absorption inhibitor
WO2009024889A2 (en) * 2007-08-21 2009-02-26 Ranbaxy Laboratories Limited Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe
WO2011019326A2 (en) * 2009-07-02 2011-02-17 Mahmut Bilgic Solubility and stability enchancing pharmaceutical formulation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2648897B2 (en) 1991-07-01 1997-09-03 塩野義製薬株式会社 Pyrimidine derivatives
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
HU227610B1 (en) 2006-09-18 2011-09-28 Richter Gedeon Nyrt Pharmaceutical compositions containing rosuvastatin potassium

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1336405A1 (en) * 2002-02-14 2003-08-20 Ranbaxy Laboratories, Ltd. Formulations of atorvastatin stabilized with alkali metal additions
WO2008101723A2 (en) * 2007-02-23 2008-08-28 Krka Pharmaceutical composition containing a cholesterol absorption inhibitor
WO2009024889A2 (en) * 2007-08-21 2009-02-26 Ranbaxy Laboratories Limited Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe
WO2011019326A2 (en) * 2009-07-02 2011-02-17 Mahmut Bilgic Solubility and stability enchancing pharmaceutical formulation

Also Published As

Publication number Publication date
WO2011139256A2 (en) 2011-11-10
EP2566465A2 (en) 2013-03-13

Similar Documents

Publication Publication Date Title
WO2011139256A3 (en) Stable rosuvastatin formulations
WO2012075383A3 (en) Bromodomain inhibitors and uses thereof
WO2013184876A8 (en) Benzo [c] isoxazoloazepine bromodomain inhibitors and uses thereof
WO2012021715A3 (en) Stable formulations of linaclotide
EP2540720A4 (en) 1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyrazine derivative and use of same as hiv integrase inhibitor
WO2012174487A3 (en) Bromodomain inhibitors and uses thereof
WO2012151512A3 (en) Bromodomain inhibitors and uses thereof
AU2014304562A8 (en) Thieno[2,3-c]pyrans as CFTR modulators
NZ603151A (en) N3-substituted-n1-sulfonyl-5-fluoropyrimidinone derivatives
WO2011056487A3 (en) Stable thickener formulations
MX367561B (en) Cosmetic composition.
WO2014101295A3 (en) Isoxazole derivative that inhibits activity of janus kinases (jaks)
WO2012001705A3 (en) Pharmaceutical compositions of (r)-lansoprazole
WO2012101653A3 (en) Modified release pharmaceutical compositions memantine
WO2014056713A3 (en) Oral care composition
WO2011095331A3 (en) Cosmetic formulation and use thereof
PH12016500865A1 (en) Composite formulation comprising tadalafil and amlodipine
MX2016001422A (en) Pharmaceutical compositions of fingolimod.
WO2011149301A3 (en) A composition comprising the extract of physalis alkekengi var. francheti hort as an active ingredient for preventing and treating inflammatory diseases
WO2011142731A3 (en) Formulations comprising a third generation cephalosporin and clavulanic acid
WO2013057741A3 (en) Pharmaceutical compositions of ursodeoxycholic acid
WO2013127615A3 (en) Personal care compositions with acidified pectins
WO2011101734A3 (en) Taste-masked powder for suspension compositions of methylprednisolone
MX2013013079A (en) Compositions comprising antibacterial agent and tazobactam.
WO2011139249A3 (en) Pharmaceutical composition comprising cefdinir

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11725996

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011725996

Country of ref document: EP